Management of squamous cell carcinoma of the head and neck: Updated European treatment recommendations

Expert Review of Anticancer Therapy

Volumn 10, Issue 3, 2010, Pages 339-344

  Ramos, Monica ^a   Benavente, Sergi ^a   Giralt, Jordi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

EGF receptor; Head and neck cancer; Human papillomavirus; Intensity modulated radiotherapy; Locally advanced head and neck carcinoma; Postoperative radiotherapy; Risk groups; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; PACLITAXEL; PANITUMUMAB;

ADVANCED CANCER; ANATOMICAL VARIATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; WART VIRUS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; EUROPE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS;

EID: 77949428730     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.10.6     Document Type: Review

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94, 153-156 (2001).
2. Gibson MK, Forastiere AA. Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art. Curr. Opin. Oncol. 16(3), 220-224 (2004).
3. Licitra L, Felip E. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 121-122 (2009).
4. Curtin H, Ishwararn H, Mancuso H, Dalley B, Caudry D, McNeil B. Comparison of CT and MRI imaging in staging of neck metastases. Radiology 207, 123-130 (1998).
5. Ng SH, Yen TC, Liao CT et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J. Nucl. Med. 46, 1136-1143 (2005).
6. Hannah A, Scott AM, Tochon-Danguy H et al. Evaluation of 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann. Surg. 236, 208-217 (2002).
7. Ng SH, Yen TC, Chang JCT et al. Prospective study of [18F] fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J. Clin. Oncol. 24, 4371-4376 (2006).
8. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F- fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J. Natl Cancer Inst. 100, 712-720 (2008).
9. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350, 1937-1944 (2004).
10. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350, 1945-1952 (2004).
11. Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (9501). Head Neck 843-849 (2005).
12. Kies MS, Harris J, Rotman MZ et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Proceedings of the 51st Annual ASTRO Meeting. Int. J. Radiat. Oncol. Biol. Phys. 75(3), S15 (2009) (Abstract 29).
13. Pignon JP, Bourhis J, Domenge C, Designe L. Meta-analysis of chemotherapy in head and neck squamous cell carcinoma. On behalf of the MACH-NC collaborative group. Lancet 355, 949-955 (2000).
14. Machtay M, Moughan J, Trotti A et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J. Clin. Oncol. 26(21), 3582-3589 (2008).
15. Adelstein DJ, Saxton JP, Rybicki LA et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J. Clin. Oncol. 24, 1064-1071 (2006).
16. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
17. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: mature efficacy results of a Phase III trial. Lancet Oncol. (In press).
18. Giralt J, Trigo JM, Nuyts S et al. A Phase 2 randomized trial of radiotherapy (RT) plus panitumumab compared to chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck: interim pooled safety analyses. ECCO 15-34th ESMO. Eur. J. Cancer 14(Suppl. 1), (2009).
19. Quon H, Langer CJ, Lee J et al. E3303: a Phase II study of cetuximab (C225) in combination with cisplatin (DDP) and definitive radiation (XRT) in unresectable squamous cell carcinoma of the head and neck (U-SCCHN). Int. J. Radiat. Oncol. Biol. Phys. 75(3), S15 Proceedings ASTRO 51 (2009).
20. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 23, 8636-8645 (2005).
21. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 357, 1695-1704 (2007).
22. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357, 1705-1715 (2007).
23. Lorch J, Haddad RI, Fasciano J et al. Long term (five-year) results of Tax324: a Phase III trial of sequential therapy comparing TPF with PF in patients with locally advanced squamous cell cancer of the head and neck. Proceedings of ECCO15-ESMO34. Eur. J. Cancer 7, (2009) (Abstract 470).
24. Grégoire V, De Neve W, Eisbruch A, Lee N, Van den Weyngaert D, Van Gestel D. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist 12, 555-564 (2007).
25. Eisbruch A, Harris J, Garden AS et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2009.04.011 (2009) (Epub ahead of print).
26. Pacholke HD, Amdur RJ, Morris CG et al. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am. J. Clin. Oncol. 28, 351-358 (2005).
27. Nutting C, A'Hern R, Rogers MS et al. First results of a Phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J. Clin. Oncol. 27, 18s (2009).
28. Pow EH, Kwong DL, McMillan AS et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 66, 981-991 (2006).
29. Peters LJ, O'Sullivan B, Giralt J et al. Radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer - results from TROG 02.02. J. Clin. Oncol. (2010) (In press).
30. Gillison ML, Harris J, Westra W et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. Proc. Am. Soc. Clin. Oncol. 27, (2009) (Abstract 6003).
31. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J. Clin. Oncol. 27, 1992-1998 (2009).
32. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus - positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer. Inst. 100, 261-269 (2008).
33. Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 24, 5630-5636 (2006).
34. Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 26, 3128-3137 (2008).
35. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin. Radiat. Oncol. 19, 63-68 (2009).